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A B S T R A C T
The aim of this retrospective study was to answer the following questions: 1) is HPV DNA test for high-risk types able
to predict lesion behaviour in women with cytological abnormalities lower than CIN3 (ASC-US, CIN1 and CIN2); 2)
how to predict the histological diagnosis CIN3, and 3) is its use in diagnostic management in these patients justified or
not? The study included 345 women (11 ASC-US, 312 CIN1 and 22 CIN2) that underwent conventional diagnostic man-
agement (repeat cytology and colposcopy with or without histology) and HPV testing for high-risk HPV types by PCR
method. The value of HPV DNA test in predicting lesion regression/persistence was assessed in 275 subjects without his-
tology. In 70 subjects, diagnostic accuracy (sensitivity, specificity, and positive and negative predictive value) of repeat cy-
tology and HPV DNA test in predicting severe intraepithelial lesion (CIN3) was determined on the basis of colposcopy
guided biopsy. The prevalence of persistent lesions was significantly higher in the group of HPV positive than in the
group of HPV negative subjects (37.7% vs. 16.4%; p<0.001). Positive HPV test was associated with a 3.1-fold risk of le-
sion persistence [OR (95% CI) =3.095 (1.65–5.82)]. However, on screening to predict the outcome of cytologically diag-
nosed cervical lesion with sensitivity of 39.7% and positive predictive value of 37.7% showed that a positive test could not
be considered a reliable indicator of lesion persistence. In contrast, the specificity of 82.5% and negative predictive value
of 83.6% suggested that a negative test result could be taken as a good indicator of lesion regression. In comparison with
repeat cytology, HPV test showed higher sensitivity (69.2% vs. 61.5%) but significantly lower specificity (63.2% vs. 93.0%)
and positive predictive value (30.0% vs. 66.7%), and comparable negative predictive value (90.0% vs. 91.4%) in predict-
ing histologically verified CIN3. In one patient with a histological diagnosis of squamous cell carcinoma with minimal
invasion, repeat cytology indicated CIN3, whereas HPV test was negative. Due to authors experience in women with cyto-
logical abnormalities lower than CIN3, HPV testing is not a method to reliably predict lesion behaviour (regression, per-
sistence) or presence of CIN3. HPV testing is of limited value in daily routine and should not be widely used until it is
definitely demonstrated to be superior to conventional methods in improving the sensitivity, specificity and positive pre-
dictive value of CIN3 and invasive carcinoma detection.
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Introduction
The main goal of cytological screening by Pap test is
identification of women with cervical lesions at an in-
creased risk of cervical carcinoma1. These women require
regular follow up and/or treatment to prevent the lesion
progression to invasive carcinoma. While there is general
consensus that women with severe cytological lesions
should be referred for additional testing without delay2,
the procedure for women with mild cytological lesions re-
mains controversial3. Recommendations for women with
atypical squamous cells of undetermined significance
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(ASC-US) and low-grade squamous intraepithelial le-
sions (LSIL) vary from conservative repeat cytology4–7
through urgent referral for colposcopy and biopsy8–11.
Such a scenario does not only increase healthcare cost
considerably12, but is also associated with unfavourable
emotional effect13.
The natural history of low-grade cytological lesions is
difficult to predict on the basis of their cytomorpholo-
gical appearance. These lesions may frequently undergo
spontaneous regression, requiring no treatment14–16. Al-
though the majority of women with ASC-US are free
from clinically significant disease, some of them develop
histologically verified high-grade cervical intraepithelial
neoplasia (CIN3) or even a more severe disease17–19.
In view of the evidence on the etiologic role of infec-
tion with the oncogenic human papillomavirus (HPV) in
the development of cervical carcinoma and CIN20–24,
HPV testing has been proposed as a triage method to
identify women at an increased risk of cervical carcinoma
that should be referred for colposcopy17,18. However, re-
sults on the benefits of HPV triage in women with am-
biguous cytology are quite controversial25–27.
The aim of this retrospective study was to answer the
following questions: 1) is HPV DNA test able to predict
lesion behaviour in women with cytological abnormali-
ties lower than CIN3 (ASC-US, CIN1 and CIN2); 2) pre-
dict histological diagnosis in CIN3 lesion; and 3) is its use
in diagnostic work-up in these patients justified or not?
Subjects and Methods
The study included 345 women with cytological find-
ing obtained on primary screening suggestive intraepi-
thelial lesions lower than CIN3 (ASC-US, CIN1 and
CIN2) that underwent HPV DNA testing for high-risk
HPV types during subsequent diagnostic-therapeutic
management including cytological and colposcopic follow
up with or without histopathology analysis (from the be-
ginning of 2005 to the end of 2008). All subjects were fol-
lowed-up for 1–3 years.
Cytological smears were obtained by a spatula and
cytobrush, applied onto the glass slide, fixed in 95% alco-
hol, and stained by the Papanicolaou method. The Cro-
atian modification of the Bethesda 2001 system was used
on classification of findings28.
HPV DNA samples were obtained by a brush (Med-
scan, Malmö, Sweden) and referred for testing in a plas-
tic cuvette with phosphate buffer (PBS). Quality control
of DNA isolated from each individual sample was as-
sessed by polymerase chain reaction (PCR) amplification
of the b-globin gene. The presence of HPV in the samples
was determined by the Roche PCR-ELISA method. The
PCR-ELISA Dig-Labelling kit (Roche Diagnostics GmbH,
Mannheim, Germany) with MY09 and MY11 consensus
primers was used for PCR reactions29. HPV detection ac-
cording to the risk level was done by use of the PCR
ELISA DIG Detection kit (Roche Diagnostics GmbH,
Mannheim, Germany), whereby a mix of L1, MY18/
MY46 or GP1/GP2 consensus primers was used on
group-specific genotyping to detect low-risk (6, 11) and
high-risk (16, 18, 31, 33, 45, 52, 55, 59, etc.) HPV. Results
obtained by PCR-ELISA were tested by amplification of
the viral genome E6/E7 region. One pair of consensus
primers (HPVpU-1M, HPVpU-2R) was used for E6/E7
gene amplification of high-risk HPV types (16, 18, 31, 33,
35, 52 and 58), whereas another pair of primers (HPVpU-
-31B, HPVpU-2R) was used for low-risk HPV types (6,
11). Amplified DNA fragments of L1-HPV, E6/E7-HPV
and b-globin were determined by 1% agarose gel electro-
phoresis and visualized by an UV-transluminator (Phar-
macia Biotech, Sweden).
In 275 subjects without histopathologic analysis, the
natural history of the cytological diagnosed lesion was
identified as regression (at least two follow up cytology
findings within at least one year were negative) or persis-
tence (at least two follow up cytology findings within at
least one year were abnormal, irrespective of the level of
abnormality). Colposcopy guided biopsy was performed
in 70 subjects.
At the time of HPV testing, the following data were
recorded in all study subjects: age, first abnormal cyto-
logical differential diagnosis, most severe cytological dif-
ferential diagnosis, finding of HPV DNA test for high-
-risk types, time (months) elapsed between the first cyto-
logical finding and HPV DNA test, and time elapsed be-
tween HPV DNA test and histological analysis.
The value of HPV DNA testing for high-risk HPV
types in predicting behaviour of a cytologically detected
abnormality was assessed by comparison of the lesion na-
tural history (regression or persistence) and HPV DNA
test result.
Diagnostic accuracy (sensitivity, specificity, positive
and negative predictive value) of repeat cytology and
HPV DNA test for high-risk HPV types in the detection
of histologically verified high-grade intraepithelial lesion
(CIN3) as an immediate precancerous lesion and the
main target of screening was assessed by comparison of
histological finding with the most severe follow up cytol-
ogy finding and HPV DNA test result.
Results
In the cohort of 345 women, the first abnormal cyto-
logical finding was ASC-US in 11, CIN1 in 312 and CIN2
in 22 women. The mean age of study subjects was 34±
10.1 (range 18–65) years. HPV test was performed at a
mean of 20.7±5.2 months of the first abnormal cytologi-
cal finding and 10.4±2.1 months before histology. Testing
for high-risk HPV types showed positive result in 91
(26.4%) and negative result in 254 (73.6%) subjects.
In 275 subjects the natural history of lesion was de-
termined without histological analysis and compared
with HPV DNA test result (Table 1). Persistence of lesion
was recorded in 58 (21.1%) and regression in 217 (78.9%)
subjects.
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The prevalence of persistent lesions was significantly
higher in the group of HPV positive women than in the
group of HPV negative women (37.7% vs. 16.4%; p<
0.001). Positive HPV test for high-risk HPV types was as-
sociated with a 3.1-fold risk of lesion persistence [OR
(95% CI)=3.095 (1.65–5.82)].
Assessment of the HPV DNA test value as a screening
test to determine the likelihood of lesion persistence,
which is an additional risk for the development of inva-
sive carcinoma, yielded a sensitivity of 39.7% (23/58),
specificity of 82.5% (179/217), positive predictive value of
37.7% (23/61) and negative predictive value of 83.6%
(179/214).
In 70 subjects, follow up cytology finding and/or col-
poscopy finding indicated histological analysis, and sam-
ples were obtained by colposcopy guided biopsy. Out of 70
samples submitted for histological analysis, 16 (22.9%)
were free from intraepithelial or invasive lesion, whereas
squamous intraepithelial lesion was found in 53 (75.7%)
samples (CIN1 in 23, CIN2 in 17 and CIN3 in 13 sam-
ples), and squamous cell carcinoma with minimal inva-
sion in one (1.4%) sample (Table 2).
Diagnostic value of repeat cytology in predicting CIN3
was determined by comparison of histological finding
with the most severe follow up cytological finding (Table
2). Cytological differential diagnosis of CIN3 in the detec-
tion of histologically verified CIN3 showed a sensitivity
of 61.5%, specificity of 93.0%, positive predictive value of
66.7% and negative predictive value of 91.4%. In one pa-
tient with a histological diagnosis of squamous cell carci-
noma with minimal invasion (CIM), cytological finding
indicated CIN3.
Diagnostic value of HPV DNA test in the detection of
CIN3 was determined by comparison of histological find-
ing and HPV test result (Table 3). HPV DNA test was
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TABLE 1
NATURAL HISTORY OF LESIONS IN RELATION TO RESULTS
OF HPV DNA TESTING FOR HIGH-RISK TYPES (N=275)
Natural history
of lesions















































































































CIM – carcinoma planocellulare cum invasione minimale
TABLE 3
HISTOLOGICAL FINDINGS IN RELATION TO RESULTS OF HPV DNA TESTING FOR HIGH-RISK TYPES (N= 70)


















































CIM – carcinoma planocellulare cum invasione minimale
positive in 30 (42.9%) and negative in 40 (57.1%) sub-
jects.
In the detection of histologically verified CIN3, HPV
DNA test showed a sensitivity of 69.2%, specificity of
63.2%, positive predictive value of 30.0% and negative
predictive value of 90.0%. In one subject with a histo-
logical diagnosis of squamous cell carcinoma (CIM), HPV
test was negative.
In comparison with differential cytology, HPV test
showed higher sensitivity in the detection of CIN3, how-
ever, with a significantly lower specificity and positive
predictive value, and a comparable negative predictive
value (Table 4).
Discussion and Conclusion
Harald zur Hausen, a German virologist, was the first
to point to the association between oncogenic HPV and
cervical carcinoma in the early 1980s20. Subsequently, a
large body of evidence has been published suggesting
that persistent infection with oncogenic HPV is a pri-
mary risk factor and a necessary (yet not sufficient)
cause of cervical carcinoma and its precursors.
The use of PCR in HPV testing has offered some hope
to solve the dilemma concerning further procedures to be
taken in women with Pap test indicating ASC-US or
LSIL30. However, in spite of the large number of studies
employing HPV test to discriminate patients that re-
quire urgent colposcopy and biopsy from those that can
be cytologically followed up by Pap test alone, the poten-
tial benefits of the wide use of HPV screening have not
yet been fully clarified31,32. Some studies point to the ben-
efits of the large-scale use of HPV testing, whereas others
are less enthusiastic, suggesting the use of this test to be
for the time being restricted to the field of research33–36.
In the present study, we retrospectively assessed the
value of HPV test versus cytological and colposcopic fol-
low up, and histology in indicated cases. Besides women
with cytological findings of ASC-Us and CIN1 (LSIL),
the study also included women with CIN2 because the
protocol for CIN1 and CIN2 is the same in our setting37.
The prevalence of HPV as detected by HPV DNA test-
ing in the study population was 26.4% (91/345). Out of
275 women with cytological and colposcopic follow up
alone, the lesion persisted in 58 (21.1%) and regressed in
217 (78.9%) subjects. The prevalence of persistent le-
sions was significantly higher in the group of HPV
positive women than in HPV negative women (37.7% vs.
16.4%; p<0.001). Positive HPV test was associated with
a 3.1-fold risk of lesion persistence [OR (95% CI)=3.095
(1.65–5.82)].
When the value of HPV test was assessed in the con-
text of predicting the outcome of cytologically diagnosed
cervical lesion, the sensitivity of 39.7% and positive pre-
dictive value of 37.7% showed that a positive test could
not be considered a reliable indicator of lesion persis-
tence. In contrast, the specificity of 82.5% and negative
predictive value of 83.6% suggested that a negative test
result could be taken as a good indicator of lesion regres-
sion.
Histological diagnosis made on colposcopy guided bi-
opsy was used as a reference standard on assessing the
value of HPV test; therefore, the possible errors that may
have occurred on biopsy specimen collection should have
been taken in consideration on result evaluation38,39 and
finding interpretation40. In addition, errors on cytologi-
cal sample collection and interpretation may have also
influenced assessment of the HPV test value.
CIN3 was found in 13 of 70 women that underwent
cervical biopsy. HPV test showed a sensitivity of 69.2%
and specificity of 63.2% in predicting CIN3. Test sensitiv-
ity and specificity are not independent measures because
an increase in sensitivity with an apparent decrease in
false-negative diagnoses may be accompanied by an in-
crease in the rate of false-positive diagnoses, and vice
versa. The connection between the test sensitivity and
specificity is best illustrated by predictive values. The
HPV test positive predictive value was 30.0% and nega-
tive predictive value 90.0%. In one subject with a histo-
logical diagnosis of squamous cell carcinoma with mini-
mal invasion, HPV test was negative.
Kulasingam et al.41 report on the HPV test sensitivity
in predicting CIN2-3 to range from 55.7% to 93.3%. How-
ever, in another study reporting highest sensitivity, the
positive predictive value varied from 17.3% to 28.3% and
specificity from 24.2% to 66.8%33. In the study conducted
by Hatch et al.42, the HPV test sensitivity in predicting
CIN2-3 in women with a cytological finding of LSIL was
67%, and in those with a cytological finding of ASC-US
60%, specificity 68% and positive predictive value 35%.
HPV test was negative in 4 of 9 women with invasive
squamous cell carcinoma.
In the present study, repeat cytology showed sensitiv-
ity of 61.5%, specificity of 93.0%, positive predictive
value of 66.7% and negative predictive value of 91.4% in
predicting CIN3. HPV test yielded a higher sensitivity,
but its specificity and positive predictive value were sig-
nificantly lower, whereas negative predictive value was
comparable to that shown by repeat cytology. As more
than 90% of study women had a primary cytological diag-
nosis of CIN1, the results could mostly be related to
LSIL. In contrast to other studies, we separated CIN2
from the HSIL group, based on our national classifica-
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TABLE 4
DIAGNOSTIC VALUE OF REPEAT CYTOLOGY AND HPV DNA







Positive predictive value 66.7% 30.0%
Negative predictive value 91.4% 90.0%
tion of cytological findings, and were therefore able to di-
rectly compare cytological and histological grades of CIN.
In their meta-analysis of nine studies assessing the
value of repeat cytology and HPV test in predicting HSIL
when primary cytological finding indicated ASC-US or a
more severe lesion, Arbyn et al.43 found the sensitivity of
cytology to range from 60.0% to 80.0%, specificity from
44.7% to 71.7%, positive predictive value from 3.8% to
22.2%, and negative predictive value from 93.4% to 97.8%.
The sensitivity of HPV test ranged from 32.4% to 58.8%.
The results of our retrospective study revealed that
HPV testing as a method of secondary screening in
women with cytological abnormalities lower than CIN3
was not useful either to identify women whose lesions
would regress or those with high-grade intraepithelial le-
sion (CIN3), or to obviate unnecessary colposcopy. While
negative HPV test did indicate a higher likelihood of le-
sion regression, positive HPV test did not exclude lesion
regression. In addition, positive HPV test suggested a
higher likelihood of histologically verified CIN3, but neg-
ative HPV test did not exclude it. Due to our experience
we would agree with the opinion that HPV testing has
only a limited value in daily routine and should not be
widely used before it is clearly demonstrated to be supe-
rior to conventional methods by increased sensitivity,
specificity and positive predictive value in detecting
CIN3 and invasive carcinoma.
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OCJENA VRIJEDNOSTI HPV DNA TESTA U OBRADI @ENA SA CITOLO[KIM
NALAZOM ASC-US, CIN1 i CIN2
S A @ E T A K
Cilj retrospektivne studije je bio odgovoriti na pitanja: mo`e li HPV DNA test u `ena s lak{im citolo{kim abnormal-
nostima (ASC-US, CIN1 i CIN2) prognozirati pona{anje lezije, mo`e li predvidjeti histolo{ku dijagnozu CIN3 i da li je
njegova primjena u dijagnosti~kom postupku kod tih `ena opravdana ili ne. U studiju je uklju~eno 345 `ena (11
ASC-US, 312 CIN1 i 22 CIN2) kojima je uz konvencionalni postupak (ponavljana citologija i kolposkopija sa ili bez
histologije) u~injen i HPV DNA test na visokorizi~ne tipove PCRmetodom. Za 275 ispitanica bez histologije je odre|ena
vrijednost HPV testa u predvi|anju regresije/perzistencije lezije. U 70 ispitanica je u~injena kolposkopski kontrolirana
biopsija na temelju koje je odre|ena dijagnosti~ka to~nost (osjetljivost, specifi~nost, pozitivna i negativna prediktivna
vrijednost) ponavljane citologije i HPV DNA testa u predvi|anju te{ke intraepitelne lezije (CIN3). U~estalost perzi-
stentnih lezija je bila zna~ajno vi{a u skupini HPV pozitivnih (37,7%) nego u skupini HPV negativnih `ena (16,4%)
(p<0,001). HPV pozitivan test pove}ava rizik perzistiranja lezije za 3,1 puta. [OR (95% CI)=3,095 (1,65–5,82)]. Me-
|utim, u predvi|anju ishoda citolo{ki dijagnosticirane cervikalne lezije, osjetljivost od 39,7% i pozitivna prediktivna
vrijednost od 37,7% ukazuju da pozitivan test na visokorizi~ne tipove nije valjani indikator za perzistiranje lezije, dok
specifi~nost od 82,5% i negativna prediktivna vrijednost od 83,6% ukazuju da je negativan test relativno dobar indi-
kator za regresiju lezije.U odnosu na ponavljanu citologiju, HPV test ima za predvi|anje histolo{ki potvr|enog CIN3
vi{u osjetljivost (69,2% prema 61,5%), ali zna~ajno ni`u specifi~nost (63,2% prema 93,0%) i pozitivnu prediktivnu vri-
jednost (30,0% prema 66,7%), te sli~nu negativnu prediktivnu vrijednost (90,0% prema 91,4%). U jedne ispitanice s
histolo{kom dijagnozom carcinoma planocellulare cum invasione minimale (CIM) ponovljeni citolo{ki je nalaz bio CIN3, a
HPV test je bio negativan. Prema na{im rezultatima HPV testiranje u `ena s citolo{kim abnormalnostima manjim od
CIN3 nije metoda kojom bi se pouzdano moglo predvidjeti pona{anje lezije (regresija, perzistiranje) ili postojanje CIN3,
pa za prakti~ara ima ograni~enu vrijednost i ne bi ga trebalo {iroko primjenjivati sve dok se jasno ne doka`e da u odnosu
na konvencionalne metode stvarno pove}ava osjetljivost, specifi~nost i pozitivnu prediktivnu vrijednost detekcije CIN3
i invazivnog karcinoma.
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